DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive Biomarkers
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Pulmonary Disease
- Type
- Observational
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 46 years and 125 years
- Gender
- Both males and females
Description
The Detection of Early lung Cancer Among Military Personnel (DECAMP) consortium is a multidisciplinary and translational research program that previously initiated the DECAMP-1 and DECAMP-2 studies for lung cancer early detection. Now, with the support of Johnson and Johnson, 3 Veterans Administrati...
The Detection of Early lung Cancer Among Military Personnel (DECAMP) consortium is a multidisciplinary and translational research program that previously initiated the DECAMP-1 and DECAMP-2 studies for lung cancer early detection. Now, with the support of Johnson and Johnson, 3 Veterans Administration Hospitals (VAH), 3 Military Treatment Facilities (MTF) and 12 academic hospitals as clinical study sites, several molecular biomarker laboratories, along with Biostatics, Bioinformatics, Pathology and Biorepository cores, we are expanding our work in lung cancer early detection.
Tracking Information
- NCT #
- NCT04165564
- Collaborators
- Johnson & Johnson
- American College of Radiology Imaging Network
- Investigators
- Principal Investigator: Ehab Billatos, MD Boston University Principal Investigator: Denise Aberle, MD University of California, Los Angeles Principal Investigator: George Washko, MD Brigham and Women's Hospital
Get Well Soon